Salih Ehsan/LinkedIn
Sep 20, 2026, 03:58
Salih Ehsan: The Complexities of HbF and HbA2
Salih Ehsan, Chief Executive Officer at Kulsoom Society of Hematology, shared a post on LinkedIn:
“HbF% and HbA2 % create lots of confusion, their ups and downs make us crazy and deviation of focus.
Their combinations with HB, MCV/ MCH, and with HbF, HbA, HbS, HB lepore, delta beta thalassemia, HPFH, Beta chain variants, alpha Thelassemia need a detective work.
I try my best to simplify games of HbA2 and HbF.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?